1-[4-[4-(2-Bicyclo[2.2.1]heptanyl)piperazin-1-yl]-3-fluorophenyl]-1,2,4-triazole-3,5-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[4-[4-(2-Bicyclo[2.2.1]heptanyl)piperazin-1-yl]-3-fluorophenyl]-1,2,4-triazole-3,5-diamine
• 英文别名: 1-[4-[4-(2-bicyclo[2.2.1]heptanyl)piperazin-1-yl]-3-fluorophenyl]-1,2,4-triazole-3,5-diamine
• 化学式: C₁₉H₂₆FN₇
• 分子量: 371.5
• InChiKey: NNUJFCSTWRNOLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  89.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140155386A1

  公开（公告）日：2014-06-05

  Bridged bicyclic aryl or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  本发明公开了桥联的双环芳基或杂环芳基取代的三唑类化合物及含有这些化合物的药物组合物，其可用于抑制受体蛋白酪氨酸激酶Axl的活性。本发明还公开了使用这些化合物治疗与Axl活性相关的疾病或病状的方法。
• DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME
  申请人：Del Mar Pharmaceuticals

  公开号：EP3217970A1

  公开（公告）日：2017-09-20
• US9353124B2
  申请人：——

  公开号：US9353124B2

  公开（公告）日：2016-05-31
• [EN] DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL EN COMBINAISON AVEC DES RAYONS, POUR TRAITER LE CANCER DU POUMON NON À PETITES CELLULES ET LE GLIOBLASTOME MULTIFORME
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2016077264A1

  公开（公告）日：2016-05-19

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.